News

The AGATA study is designed to evaluate the safety and efficacy of TTP399 following six months administration in subjects with type 2 diabetes mellitus on a stable dose

PKAN is a rare and life-threatening autosomal recessive neurodegenerative disorder. There are no approved treatments currently available for PKAN, which is believed to affect one to three persons

With the acceptance of PIP, the company will be able to submit a marketing authorization application (MAA) in Europe following completion of the Viaskin Peanut phase III program.

As part of the deal, Vertex will have worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, including P-1037 and P-1055. Parion will receive an upfront payment

About the trial The trial reached its targeted enrollment of nine patients, who are two years of age or greater but less than 12 years of age, with

HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, and cannot be accounted for by another medical physical or psychiatric

This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic

Adapt has partnerd with biopharmaceutical firm Lightlake Therapeutics to develop treatments for opioid overdose. In December, Lightlake has agreed to license its opioid overdose reversal treatment to a

AR-12 is an orally-available small molecule. Data reported earlier shows that the mechanism of action of the molecule may include induction of host cell autophagy and inhibition of